Kwality Pharmaceuticals Limited (KPL) fundamentals
Kwality Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as KPL (ISIN INE552U01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Kwality Pharmaceuticals Limited does
Kwality Pharmaceuticals Limited is an India-based company, which engages in the manufacturing & trading in pharmaceuticals & allied products. It engages in the business of manufacturers, buyers and sellers of and dealers in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. It also engages in research and development activities. It manufactures exports pharmaceutical formulations in liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, oral rehydration solutions (ORS), and others in various categories like beta lactam and non-beta lactam, hormones, cytotoxic (oncology) and effervescent. The Company has approximately 48 different sections available at their production centers. Its subsidiary is Kwality Pharmaceuticals Africa Limitada.
Valuation and market data
| Last close | ₹3520.00 |
|---|---|
| Market capitalisation | ₹3,653 crore |
| Enterprise value | ₹3,689 crore |
| P/E (TTM) | 54.24 |
| Price to book | 11.07 |
| Price to sales (TTM) | 4.05 |
| Book value per share | ₹317.90 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Apr 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹506 crore | ₹89 crore | ₹67 crore | 64.90 |
| Mar 2025 | ₹372 crore | ₹54 crore | ₹40 crore | 38.44 |
| Mar 2024 | ₹309 crore | ₹31 crore | ₹24 crore | 23.11 |
| Mar 2023 | ₹254 crore | ₹26 crore | ₹19 crore | 18.45 |
| Mar 2022 | ₹460 crore | ₹162 crore | ₹120 crore | 115.36 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 54.9% |
|---|---|
| Foreign institutions (FII) | 3.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.6% |
| Retail and others | 41.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.